IP Verse

Retroviral And Lentiviral Vectors - EP3265570

The patent EP3265570 was granted to Autolus on Jul 23, 2025. The application was originally filed on Mar 1, 2016 under application number EP16709502A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3265570

AUTOLUS
Application Number
EP16709502A
Filing Date
Mar 1, 2016
Status
Patent Maintained As Amended
Jun 20, 2025
Grant Date
Jul 23, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MARGARET DIXONFeb 4, 2022MEWBURN ELLISADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2006007539
INTERNATIONAL-SEARCH-REPORTWO2007095201
INTERNATIONAL-SEARCH-REPORTWO2009014726
INTERNATIONAL-SEARCH-REPORTWO2011067553
INTERNATIONAL-SEARCH-REPORTWO9705266
OPPOSITIONWO2006007539
OPPOSITIONWO2009014726
OPPOSITIONWO2011067553
OPPOSITIONWO2016030690

Non-Patent Literature (NPL) Citations (13) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- VERHOEYEN et al., "SURFACE-ENGINEERING OF LENTIVIRAL VECTORS", The Journal of Gene Medicine, US , (20040201), vol. 6, no. SUPPL. 01, doi:10.1002/jgm.494, ISSN 1099-498X, pages S83 - S94, XP009054227
OPPOSITION- Yang et al., "Cell Type-Specific Targeting with Surface-Engineered Lentiviral Vectors Co-displaying OKT3 Antibody and Fusogenic Molecule", PHARMACEUTICAL RESEARCH, NL , (20090304), vol. 26, no. 6, doi:10.1007/s11095-009-9853-y, ISSN 1573-904X, pages 1432 - 1445, XP019686189
OPPOSITION- RIDDELL et al., "The use of anti-CD3 and anti-CD28 monolocnal antibodies to clone and expand human antigen-specific T cells", Journal of Immunological Methods, NL , (19900101), vol. 128, no. 2, doi:10.1016/0022-1759(90)90210-M, ISSN 0022-1759, pages 189 - 201, XP003011565
OPPOSITION- Allan et al., "Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion", Molecular therapy- methods & clinical development, GB , (20210301), vol. 20, doi:10.1016/j.omtm.2021.01.008, ISSN 2329-0501, pages 559 - 571, XP055893725
OPPOSITION- Gerstmayer et al., "Construction and expression in the yeast Pichia pastoris of functionally active soluble forms of the human costimulatory molecules B7‐1 and B7‐2 and the B7 counter‐receptor CTLA‐4", FEBS Letters, NL , (19971107), vol. 407, no. 1, doi:10.1016/S0014-5793(97)00294-9, ISSN 0014-5793, pages 63 - 68, XP071236130
OPPOSITION- Derdak et al., "Direct stimulation of T lymphocytes by immunosomes: Virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20060829), vol. 103, no. 35, doi:10.1073/pnas.0602283103, ISSN 0027-8424, pages 13144 - 13149, XP055893683
OPPOSITION- Wang et al., "Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale", Journal of Immunotherapy, (20120101), vol. 35, no. 9, doi:10.1097/CJI.0b013e318270dec7, ISSN 15249557, pages 689 - 701, XP055211902
OPPOSITION- Goodier et al., "CD28 is not directly involved in the response of human CD3−CD56+ natural killer cells to lipopolysaccharide: a role for T cells", Immunology, GB , (20040330), vol. 111, no. 4, doi:10.1111/j.0019-2805.2004.01834.x, ISSN 0019-2805, pages 384 - 390, XP071275052
OPPOSITION- E. Verhoeyen et al., "IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes", Blood, US , (20030315), vol. 101, no. 6, doi:10.1182/blood-2002-07-2224, ISSN 0006-4971, pages 2167 - 2174, XP055272100
OPPOSITION- TSUJI T, ET AL., "GENERATION OF TUMOR-SPECIFIC, HLA CLASS I-RESTRICTED HUMAN TH1 AND TC1 CELLS BY CELL ENGINEERING WITH TUMOR PEPTIDE-SPECIFIC T-CELL RECEPTOR GENES", Blood, US , (20050715), vol. 106, no. 2, doi:10.1182/blood-2004-09-3663, ISSN 0006-4971, pages 470 - 476, XP009065565
OPPOSITION- Paszkiet et al., "CD86 and CD54 Co-Expression on VSV-G Pseudotyped HIV-1 Based Vectors Improves Transduction and Activation of Human Primary CD4+ T Lymphocytes.", Blood, US , (20041116), vol. 104, no. 11, doi:10.1182/blood.V104.11.1754.1754, ISSN 0006-4971, XP086655037
OPPOSITION- MAURICE M, ET AL, "Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide.", Blood, US , (20020401), vol. 99, no. 7, doi:10.1182/blood.V99.7.2342, ISSN 0006-4971, pages 2342 - 2350, XP002346143
OPPOSITION- Mosca et al., "Antigen-presenting particle technology using inactivated surface-engineered viruses: induction of immune responses against infectious agents", RETROVIROLOGY, GB , (20070515), vol. 4, no. 1, doi:10.1186/1742-4690-4-32, ISSN 1742-4690, page 32, XP021030277

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents